nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—Hypomagnesaemia—Epirubicin—bone cancer	0.00808	0.00808	CcSEcCtD
Metolazone—Hypomagnesaemia—Doxorubicin—bone cancer	0.00748	0.00748	CcSEcCtD
Metolazone—Hypercalcaemia—Epirubicin—bone cancer	0.00739	0.00739	CcSEcCtD
Metolazone—Hyponatraemia—Cisplatin—bone cancer	0.00728	0.00728	CcSEcCtD
Metolazone—Hypercalcaemia—Doxorubicin—bone cancer	0.00684	0.00684	CcSEcCtD
Metolazone—Petechiae—Methotrexate—bone cancer	0.00667	0.00667	CcSEcCtD
Metolazone—Orthostatic hypotension—Cisplatin—bone cancer	0.00663	0.00663	CcSEcCtD
Metolazone—Hypokalaemia—Cisplatin—bone cancer	0.0066	0.0066	CcSEcCtD
Metolazone—Cramp muscle—Cisplatin—bone cancer	0.00653	0.00653	CcSEcCtD
Metolazone—Glycosuria—Epirubicin—bone cancer	0.00634	0.00634	CcSEcCtD
Metolazone—Petechiae—Epirubicin—bone cancer	0.00624	0.00624	CcSEcCtD
Metolazone—Pancreatitis—Cisplatin—bone cancer	0.00615	0.00615	CcSEcCtD
Metolazone—Abdominal discomfort—Cisplatin—bone cancer	0.00601	0.00601	CcSEcCtD
Metolazone—Hyperuricaemia—Methotrexate—bone cancer	0.00591	0.00591	CcSEcCtD
Metolazone—Glycosuria—Doxorubicin—bone cancer	0.00586	0.00586	CcSEcCtD
Metolazone—Jaundice cholestatic—Epirubicin—bone cancer	0.00584	0.00584	CcSEcCtD
Metolazone—Petechiae—Doxorubicin—bone cancer	0.00577	0.00577	CcSEcCtD
Metolazone—Blood uric acid increased—Methotrexate—bone cancer	0.00559	0.00559	CcSEcCtD
Metolazone—Hyperuricaemia—Epirubicin—bone cancer	0.00553	0.00553	CcSEcCtD
Metolazone—Nocturia—Epirubicin—bone cancer	0.00553	0.00553	CcSEcCtD
Metolazone—Neuropathy peripheral—Cisplatin—bone cancer	0.00548	0.00548	CcSEcCtD
Metolazone—Jaundice cholestatic—Doxorubicin—bone cancer	0.00541	0.00541	CcSEcCtD
Metolazone—Skin exfoliation—Methotrexate—bone cancer	0.00524	0.00524	CcSEcCtD
Metolazone—Blood uric acid increased—Epirubicin—bone cancer	0.00523	0.00523	CcSEcCtD
Metolazone—Nocturia—Doxorubicin—bone cancer	0.00512	0.00512	CcSEcCtD
Metolazone—Hyperuricaemia—Doxorubicin—bone cancer	0.00512	0.00512	CcSEcCtD
Metolazone—Skin exfoliation—Epirubicin—bone cancer	0.0049	0.0049	CcSEcCtD
Metolazone—Blood urea increased—Epirubicin—bone cancer	0.00485	0.00485	CcSEcCtD
Metolazone—Blood uric acid increased—Doxorubicin—bone cancer	0.00484	0.00484	CcSEcCtD
Metolazone—Neuropathy—Epirubicin—bone cancer	0.00482	0.00482	CcSEcCtD
Metolazone—Tinnitus—Cisplatin—bone cancer	0.00468	0.00468	CcSEcCtD
Metolazone—Photosensitivity—Methotrexate—bone cancer	0.00453	0.00453	CcSEcCtD
Metolazone—Skin exfoliation—Doxorubicin—bone cancer	0.00453	0.00453	CcSEcCtD
Metolazone—Blood urea increased—Doxorubicin—bone cancer	0.00448	0.00448	CcSEcCtD
Metolazone—Neuropathy—Doxorubicin—bone cancer	0.00446	0.00446	CcSEcCtD
Metolazone—Flatulence—Cisplatin—bone cancer	0.00431	0.00431	CcSEcCtD
Metolazone—Photosensitivity—Epirubicin—bone cancer	0.00424	0.00424	CcSEcCtD
Metolazone—Muscle spasms—Cisplatin—bone cancer	0.0042	0.0042	CcSEcCtD
Metolazone—Vascular purpura—Epirubicin—bone cancer	0.00416	0.00416	CcSEcCtD
Metolazone—Vision blurred—Cisplatin—bone cancer	0.00412	0.00412	CcSEcCtD
Metolazone—Lethargy—Methotrexate—bone cancer	0.00406	0.00406	CcSEcCtD
Metolazone—Ill-defined disorder—Cisplatin—bone cancer	0.00405	0.00405	CcSEcCtD
Metolazone—Anaemia—Cisplatin—bone cancer	0.00404	0.00404	CcSEcCtD
Metolazone—Malaise—Cisplatin—bone cancer	0.00394	0.00394	CcSEcCtD
Metolazone—Photosensitivity—Doxorubicin—bone cancer	0.00393	0.00393	CcSEcCtD
Metolazone—Leukopenia—Cisplatin—bone cancer	0.00391	0.00391	CcSEcCtD
Metolazone—Purpura—Epirubicin—bone cancer	0.00387	0.00387	CcSEcCtD
Metolazone—Vascular purpura—Doxorubicin—bone cancer	0.00385	0.00385	CcSEcCtD
Metolazone—Lethargy—Epirubicin—bone cancer	0.0038	0.0038	CcSEcCtD
Metolazone—Hyponatraemia—Epirubicin—bone cancer	0.00374	0.00374	CcSEcCtD
Metolazone—Anxiety—Cisplatin—bone cancer	0.00371	0.00371	CcSEcCtD
Metolazone—Discomfort—Cisplatin—bone cancer	0.00368	0.00368	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.00359	0.00359	CcSEcCtD
Metolazone—Purpura—Doxorubicin—bone cancer	0.00358	0.00358	CcSEcCtD
Metolazone—Lethargy—Doxorubicin—bone cancer	0.00352	0.00352	CcSEcCtD
Metolazone—Thrombocytopenia—Cisplatin—bone cancer	0.00349	0.00349	CcSEcCtD
Metolazone—Hyponatraemia—Doxorubicin—bone cancer	0.00346	0.00346	CcSEcCtD
Metolazone—Dry skin—Epirubicin—bone cancer	0.00342	0.00342	CcSEcCtD
Metolazone—Orthostatic hypotension—Epirubicin—bone cancer	0.0034	0.0034	CcSEcCtD
Metolazone—Anorexia—Cisplatin—bone cancer	0.0034	0.0034	CcSEcCtD
Metolazone—Hypokalaemia—Epirubicin—bone cancer	0.00339	0.00339	CcSEcCtD
Metolazone—Pancreatitis—Methotrexate—bone cancer	0.00337	0.00337	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.00336	0.00336	CcSEcCtD
Metolazone—Abdominal discomfort—Methotrexate—bone cancer	0.0033	0.0033	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00325	0.00325	CcSEcCtD
Metolazone—Abdominal distension—Epirubicin—bone cancer	0.00324	0.00324	CcSEcCtD
Metolazone—Paraesthesia—Cisplatin—bone cancer	0.0032	0.0032	CcSEcCtD
Metolazone—Erectile dysfunction—Methotrexate—bone cancer	0.00317	0.00317	CcSEcCtD
Metolazone—Dry skin—Doxorubicin—bone cancer	0.00316	0.00316	CcSEcCtD
Metolazone—Pancreatitis—Epirubicin—bone cancer	0.00316	0.00316	CcSEcCtD
Metolazone—Orthostatic hypotension—Doxorubicin—bone cancer	0.00315	0.00315	CcSEcCtD
Metolazone—Photosensitivity reaction—Methotrexate—bone cancer	0.00314	0.00314	CcSEcCtD
Metolazone—Hypokalaemia—Doxorubicin—bone cancer	0.00314	0.00314	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.0031	0.0031	CcSEcCtD
Metolazone—Decreased appetite—Cisplatin—bone cancer	0.0031	0.0031	CcSEcCtD
Metolazone—Drowsiness—Methotrexate—bone cancer	0.00307	0.00307	CcSEcCtD
Metolazone—Pain—Cisplatin—bone cancer	0.00305	0.00305	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.00304	0.00304	CcSEcCtD
Metolazone—Abdominal distension—Doxorubicin—bone cancer	0.003	0.003	CcSEcCtD
Metolazone—Photosensitivity reaction—Epirubicin—bone cancer	0.00294	0.00294	CcSEcCtD
Metolazone—Feeling abnormal—Cisplatin—bone cancer	0.00294	0.00294	CcSEcCtD
Metolazone—Pancreatitis—Doxorubicin—bone cancer	0.00292	0.00292	CcSEcCtD
Metolazone—Hyperglycaemia—Epirubicin—bone cancer	0.0029	0.0029	CcSEcCtD
Metolazone—Epistaxis—Methotrexate—bone cancer	0.00289	0.00289	CcSEcCtD
Metolazone—Drowsiness—Epirubicin—bone cancer	0.00287	0.00287	CcSEcCtD
Metolazone—Agranulocytosis—Methotrexate—bone cancer	0.00286	0.00286	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00285	0.00285	CcSEcCtD
Metolazone—Neuropathy peripheral—Epirubicin—bone cancer	0.00281	0.00281	CcSEcCtD
Metolazone—Hepatitis—Methotrexate—bone cancer	0.00275	0.00275	CcSEcCtD
Metolazone—Photosensitivity reaction—Doxorubicin—bone cancer	0.00272	0.00272	CcSEcCtD
Metolazone—Epistaxis—Epirubicin—bone cancer	0.00271	0.00271	CcSEcCtD
Metolazone—Hyperglycaemia—Doxorubicin—bone cancer	0.00269	0.00269	CcSEcCtD
Metolazone—Agranulocytosis—Epirubicin—bone cancer	0.00268	0.00268	CcSEcCtD
Metolazone—Drowsiness—Doxorubicin—bone cancer	0.00266	0.00266	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.00263	0.00263	CcSEcCtD
Metolazone—Hypersensitivity—Cisplatin—bone cancer	0.00263	0.00263	CcSEcCtD
Metolazone—Erythema multiforme—Methotrexate—bone cancer	0.0026	0.0026	CcSEcCtD
Metolazone—Neuropathy peripheral—Doxorubicin—bone cancer	0.0026	0.0026	CcSEcCtD
Metolazone—Hepatitis—Epirubicin—bone cancer	0.00258	0.00258	CcSEcCtD
Metolazone—Tinnitus—Methotrexate—bone cancer	0.00257	0.00257	CcSEcCtD
Metolazone—Asthenia—Cisplatin—bone cancer	0.00256	0.00256	CcSEcCtD
Metolazone—Epistaxis—Doxorubicin—bone cancer	0.00251	0.00251	CcSEcCtD
Metolazone—Agranulocytosis—Doxorubicin—bone cancer	0.00248	0.00248	CcSEcCtD
Metolazone—Chills—Methotrexate—bone cancer	0.00247	0.00247	CcSEcCtD
Metolazone—Diarrhoea—Cisplatin—bone cancer	0.00244	0.00244	CcSEcCtD
Metolazone—Erythema multiforme—Epirubicin—bone cancer	0.00244	0.00244	CcSEcCtD
Metolazone—Tinnitus—Epirubicin—bone cancer	0.0024	0.0024	CcSEcCtD
Metolazone—Hepatitis—Doxorubicin—bone cancer	0.00238	0.00238	CcSEcCtD
Metolazone—Dysgeusia—Methotrexate—bone cancer	0.00235	0.00235	CcSEcCtD
Metolazone—Back pain—Methotrexate—bone cancer	0.00232	0.00232	CcSEcCtD
Metolazone—Chills—Epirubicin—bone cancer	0.00231	0.00231	CcSEcCtD
Metolazone—Vomiting—Cisplatin—bone cancer	0.00227	0.00227	CcSEcCtD
Metolazone—Vision blurred—Methotrexate—bone cancer	0.00226	0.00226	CcSEcCtD
Metolazone—Erythema multiforme—Doxorubicin—bone cancer	0.00225	0.00225	CcSEcCtD
Metolazone—Rash—Cisplatin—bone cancer	0.00225	0.00225	CcSEcCtD
Metolazone—Dermatitis—Cisplatin—bone cancer	0.00225	0.00225	CcSEcCtD
Metolazone—Ill-defined disorder—Methotrexate—bone cancer	0.00222	0.00222	CcSEcCtD
Metolazone—Tinnitus—Doxorubicin—bone cancer	0.00222	0.00222	CcSEcCtD
Metolazone—Anaemia—Methotrexate—bone cancer	0.00222	0.00222	CcSEcCtD
Metolazone—Flatulence—Epirubicin—bone cancer	0.00221	0.00221	CcSEcCtD
Metolazone—Tension—Epirubicin—bone cancer	0.0022	0.0022	CcSEcCtD
Metolazone—Dysgeusia—Epirubicin—bone cancer	0.0022	0.0022	CcSEcCtD
Metolazone—Nervousness—Epirubicin—bone cancer	0.00218	0.00218	CcSEcCtD
Metolazone—Back pain—Epirubicin—bone cancer	0.00217	0.00217	CcSEcCtD
Metolazone—Malaise—Methotrexate—bone cancer	0.00216	0.00216	CcSEcCtD
Metolazone—Muscle spasms—Epirubicin—bone cancer	0.00216	0.00216	CcSEcCtD
Metolazone—Vertigo—Methotrexate—bone cancer	0.00215	0.00215	CcSEcCtD
Metolazone—Leukopenia—Methotrexate—bone cancer	0.00215	0.00215	CcSEcCtD
Metolazone—Chills—Doxorubicin—bone cancer	0.00214	0.00214	CcSEcCtD
Metolazone—Nausea—Cisplatin—bone cancer	0.00212	0.00212	CcSEcCtD
Metolazone—Vision blurred—Epirubicin—bone cancer	0.00211	0.00211	CcSEcCtD
Metolazone—Cough—Methotrexate—bone cancer	0.00209	0.00209	CcSEcCtD
Metolazone—Ill-defined disorder—Epirubicin—bone cancer	0.00208	0.00208	CcSEcCtD
Metolazone—Anaemia—Epirubicin—bone cancer	0.00207	0.00207	CcSEcCtD
Metolazone—Agitation—Epirubicin—bone cancer	0.00206	0.00206	CcSEcCtD
Metolazone—Flatulence—Doxorubicin—bone cancer	0.00205	0.00205	CcSEcCtD
Metolazone—Chest pain—Methotrexate—bone cancer	0.00204	0.00204	CcSEcCtD
Metolazone—Arthralgia—Methotrexate—bone cancer	0.00204	0.00204	CcSEcCtD
Metolazone—Tension—Doxorubicin—bone cancer	0.00204	0.00204	CcSEcCtD
Metolazone—Dysgeusia—Doxorubicin—bone cancer	0.00203	0.00203	CcSEcCtD
Metolazone—Malaise—Epirubicin—bone cancer	0.00202	0.00202	CcSEcCtD
Metolazone—Discomfort—Methotrexate—bone cancer	0.00202	0.00202	CcSEcCtD
Metolazone—Nervousness—Doxorubicin—bone cancer	0.00202	0.00202	CcSEcCtD
Metolazone—Vertigo—Epirubicin—bone cancer	0.00202	0.00202	CcSEcCtD
Metolazone—Syncope—Epirubicin—bone cancer	0.00201	0.00201	CcSEcCtD
Metolazone—Leukopenia—Epirubicin—bone cancer	0.00201	0.00201	CcSEcCtD
Metolazone—Back pain—Doxorubicin—bone cancer	0.00201	0.00201	CcSEcCtD
Metolazone—Muscle spasms—Doxorubicin—bone cancer	0.002	0.002	CcSEcCtD
Metolazone—Palpitations—Epirubicin—bone cancer	0.00198	0.00198	CcSEcCtD
Metolazone—Loss of consciousness—Epirubicin—bone cancer	0.00197	0.00197	CcSEcCtD
Metolazone—Cough—Epirubicin—bone cancer	0.00196	0.00196	CcSEcCtD
Metolazone—Vision blurred—Doxorubicin—bone cancer	0.00196	0.00196	CcSEcCtD
Metolazone—Hypertension—Epirubicin—bone cancer	0.00194	0.00194	CcSEcCtD
Metolazone—Ill-defined disorder—Doxorubicin—bone cancer	0.00193	0.00193	CcSEcCtD
Metolazone—Anaemia—Doxorubicin—bone cancer	0.00192	0.00192	CcSEcCtD
Metolazone—Thrombocytopenia—Methotrexate—bone cancer	0.00192	0.00192	CcSEcCtD
Metolazone—Arthralgia—Epirubicin—bone cancer	0.00191	0.00191	CcSEcCtD
Metolazone—Chest pain—Epirubicin—bone cancer	0.00191	0.00191	CcSEcCtD
Metolazone—Agitation—Doxorubicin—bone cancer	0.00191	0.00191	CcSEcCtD
Metolazone—Anxiety—Epirubicin—bone cancer	0.0019	0.0019	CcSEcCtD
Metolazone—Discomfort—Epirubicin—bone cancer	0.00189	0.00189	CcSEcCtD
Metolazone—Malaise—Doxorubicin—bone cancer	0.00187	0.00187	CcSEcCtD
Metolazone—Dry mouth—Epirubicin—bone cancer	0.00187	0.00187	CcSEcCtD
Metolazone—Vertigo—Doxorubicin—bone cancer	0.00187	0.00187	CcSEcCtD
Metolazone—Anorexia—Methotrexate—bone cancer	0.00187	0.00187	CcSEcCtD
Metolazone—Syncope—Doxorubicin—bone cancer	0.00186	0.00186	CcSEcCtD
Metolazone—Leukopenia—Doxorubicin—bone cancer	0.00186	0.00186	CcSEcCtD
Metolazone—Palpitations—Doxorubicin—bone cancer	0.00183	0.00183	CcSEcCtD
Metolazone—Loss of consciousness—Doxorubicin—bone cancer	0.00182	0.00182	CcSEcCtD
Metolazone—Cough—Doxorubicin—bone cancer	0.00181	0.00181	CcSEcCtD
Metolazone—Shock—Epirubicin—bone cancer	0.0018	0.0018	CcSEcCtD
Metolazone—Thrombocytopenia—Epirubicin—bone cancer	0.00179	0.00179	CcSEcCtD
Metolazone—Hypertension—Doxorubicin—bone cancer	0.00179	0.00179	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00178	0.00178	CcSEcCtD
Metolazone—Insomnia—Methotrexate—bone cancer	0.00177	0.00177	CcSEcCtD
Metolazone—Arthralgia—Doxorubicin—bone cancer	0.00177	0.00177	CcSEcCtD
Metolazone—Chest pain—Doxorubicin—bone cancer	0.00177	0.00177	CcSEcCtD
Metolazone—Anxiety—Doxorubicin—bone cancer	0.00176	0.00176	CcSEcCtD
Metolazone—Paraesthesia—Methotrexate—bone cancer	0.00176	0.00176	CcSEcCtD
Metolazone—Discomfort—Doxorubicin—bone cancer	0.00175	0.00175	CcSEcCtD
Metolazone—Anorexia—Epirubicin—bone cancer	0.00175	0.00175	CcSEcCtD
Metolazone—Somnolence—Methotrexate—bone cancer	0.00174	0.00174	CcSEcCtD
Metolazone—Dry mouth—Doxorubicin—bone cancer	0.00173	0.00173	CcSEcCtD
Metolazone—Dyspepsia—Methotrexate—bone cancer	0.00172	0.00172	CcSEcCtD
Metolazone—Decreased appetite—Methotrexate—bone cancer	0.0017	0.0017	CcSEcCtD
Metolazone—Fatigue—Methotrexate—bone cancer	0.00169	0.00169	CcSEcCtD
Metolazone—Pain—Methotrexate—bone cancer	0.00167	0.00167	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00167	0.00167	CcSEcCtD
Metolazone—Shock—Doxorubicin—bone cancer	0.00167	0.00167	CcSEcCtD
Metolazone—Thrombocytopenia—Doxorubicin—bone cancer	0.00166	0.00166	CcSEcCtD
Metolazone—Insomnia—Epirubicin—bone cancer	0.00166	0.00166	CcSEcCtD
Metolazone—Paraesthesia—Epirubicin—bone cancer	0.00164	0.00164	CcSEcCtD
Metolazone—Somnolence—Epirubicin—bone cancer	0.00163	0.00163	CcSEcCtD
Metolazone—Anorexia—Doxorubicin—bone cancer	0.00162	0.00162	CcSEcCtD
Metolazone—Feeling abnormal—Methotrexate—bone cancer	0.00161	0.00161	CcSEcCtD
Metolazone—Dyspepsia—Epirubicin—bone cancer	0.00161	0.00161	CcSEcCtD
Metolazone—Gastrointestinal pain—Methotrexate—bone cancer	0.0016	0.0016	CcSEcCtD
Metolazone—Decreased appetite—Epirubicin—bone cancer	0.00159	0.00159	CcSEcCtD
Metolazone—Fatigue—Epirubicin—bone cancer	0.00158	0.00158	CcSEcCtD
Metolazone—Constipation—Epirubicin—bone cancer	0.00157	0.00157	CcSEcCtD
Metolazone—Pain—Epirubicin—bone cancer	0.00157	0.00157	CcSEcCtD
Metolazone—Urticaria—Methotrexate—bone cancer	0.00155	0.00155	CcSEcCtD
Metolazone—Abdominal pain—Methotrexate—bone cancer	0.00155	0.00155	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00154	0.00154	CcSEcCtD
Metolazone—Insomnia—Doxorubicin—bone cancer	0.00153	0.00153	CcSEcCtD
Metolazone—Paraesthesia—Doxorubicin—bone cancer	0.00152	0.00152	CcSEcCtD
Metolazone—Feeling abnormal—Epirubicin—bone cancer	0.00151	0.00151	CcSEcCtD
Metolazone—Somnolence—Doxorubicin—bone cancer	0.00151	0.00151	CcSEcCtD
Metolazone—Gastrointestinal pain—Epirubicin—bone cancer	0.0015	0.0015	CcSEcCtD
Metolazone—Dyspepsia—Doxorubicin—bone cancer	0.00149	0.00149	CcSEcCtD
Metolazone—Decreased appetite—Doxorubicin—bone cancer	0.00147	0.00147	CcSEcCtD
Metolazone—Fatigue—Doxorubicin—bone cancer	0.00146	0.00146	CcSEcCtD
Metolazone—Urticaria—Epirubicin—bone cancer	0.00145	0.00145	CcSEcCtD
Metolazone—Pain—Doxorubicin—bone cancer	0.00145	0.00145	CcSEcCtD
Metolazone—Constipation—Doxorubicin—bone cancer	0.00145	0.00145	CcSEcCtD
Metolazone—Abdominal pain—Epirubicin—bone cancer	0.00145	0.00145	CcSEcCtD
Metolazone—Hypersensitivity—Methotrexate—bone cancer	0.00144	0.00144	CcSEcCtD
Metolazone—Asthenia—Methotrexate—bone cancer	0.0014	0.0014	CcSEcCtD
Metolazone—Feeling abnormal—Doxorubicin—bone cancer	0.0014	0.0014	CcSEcCtD
Metolazone—Gastrointestinal pain—Doxorubicin—bone cancer	0.00139	0.00139	CcSEcCtD
Metolazone—Pruritus—Methotrexate—bone cancer	0.00138	0.00138	CcSEcCtD
Metolazone—Hypersensitivity—Epirubicin—bone cancer	0.00135	0.00135	CcSEcCtD
Metolazone—Urticaria—Doxorubicin—bone cancer	0.00135	0.00135	CcSEcCtD
Metolazone—Abdominal pain—Doxorubicin—bone cancer	0.00134	0.00134	CcSEcCtD
Metolazone—Diarrhoea—Methotrexate—bone cancer	0.00134	0.00134	CcSEcCtD
Metolazone—Asthenia—Epirubicin—bone cancer	0.00131	0.00131	CcSEcCtD
Metolazone—Pruritus—Epirubicin—bone cancer	0.0013	0.0013	CcSEcCtD
Metolazone—Dizziness—Methotrexate—bone cancer	0.00129	0.00129	CcSEcCtD
Metolazone—Diarrhoea—Epirubicin—bone cancer	0.00125	0.00125	CcSEcCtD
Metolazone—Hypersensitivity—Doxorubicin—bone cancer	0.00125	0.00125	CcSEcCtD
Metolazone—Vomiting—Methotrexate—bone cancer	0.00124	0.00124	CcSEcCtD
Metolazone—Rash—Methotrexate—bone cancer	0.00123	0.00123	CcSEcCtD
Metolazone—Dermatitis—Methotrexate—bone cancer	0.00123	0.00123	CcSEcCtD
Metolazone—Headache—Methotrexate—bone cancer	0.00123	0.00123	CcSEcCtD
Metolazone—Asthenia—Doxorubicin—bone cancer	0.00122	0.00122	CcSEcCtD
Metolazone—Dizziness—Epirubicin—bone cancer	0.00121	0.00121	CcSEcCtD
Metolazone—Pruritus—Doxorubicin—bone cancer	0.0012	0.0012	CcSEcCtD
Metolazone—Vomiting—Epirubicin—bone cancer	0.00116	0.00116	CcSEcCtD
Metolazone—Nausea—Methotrexate—bone cancer	0.00116	0.00116	CcSEcCtD
Metolazone—Diarrhoea—Doxorubicin—bone cancer	0.00116	0.00116	CcSEcCtD
Metolazone—Rash—Epirubicin—bone cancer	0.00115	0.00115	CcSEcCtD
Metolazone—Dermatitis—Epirubicin—bone cancer	0.00115	0.00115	CcSEcCtD
Metolazone—Headache—Epirubicin—bone cancer	0.00115	0.00115	CcSEcCtD
Metolazone—Dizziness—Doxorubicin—bone cancer	0.00112	0.00112	CcSEcCtD
Metolazone—Nausea—Epirubicin—bone cancer	0.00109	0.00109	CcSEcCtD
Metolazone—Vomiting—Doxorubicin—bone cancer	0.00108	0.00108	CcSEcCtD
Metolazone—Rash—Doxorubicin—bone cancer	0.00107	0.00107	CcSEcCtD
Metolazone—Dermatitis—Doxorubicin—bone cancer	0.00107	0.00107	CcSEcCtD
Metolazone—Headache—Doxorubicin—bone cancer	0.00106	0.00106	CcSEcCtD
Metolazone—Nausea—Doxorubicin—bone cancer	0.00101	0.00101	CcSEcCtD
